Veru (NASDAQ:VERU) Vs. ARWR, GLPG, CERE, ZLAB, BHC, MRTX, CVAC, BPMC, CYTK, and RARE
Should you be buying Veru stock or one of its competitors? The main competitors of Veru include Arrowhead Pharmaceuticals (ARWR), Galapagos (GLPG), Cerevel Therapeutics (CERE), Zai Lab (ZLAB), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), CureVac (CVAC), Blueprint Medicines (BPMC), Cytokinetics (CYTK), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "personal products" industry.These companies are all part of the "pharmaceutical preparations" industry.
Veru vs.
Veru (NASDAQ:VERU) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.
Veru has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.
Veru currently has a consensus price target of $35.40, indicating a potential upside of 164.57%. Arrowhead Pharmaceuticals has a consensus price target of $72.40, indicating a potential upside of 99.94%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Arrowhead Pharmaceuticals.
Veru has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Veru is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
29.1% of Veru shares are held by institutional investors. Comparatively, 64.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 23.1% of Veru shares are held by insiders. Comparatively, 3.5% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Arrowhead Pharmaceuticals received 236 more outperform votes than Veru when rated by MarketBeat users. However, 70.81% of users gave Veru an outperform vote while only 67.03% of users gave Arrowhead Pharmaceuticals an outperform vote.
Arrowhead Pharmaceuticals has a net margin of -42.44% compared to Veru's net margin of -45.56%. Veru's return on equity of -18.64% beat Arrowhead Pharmaceuticals' return on equity.
In the previous week, Veru had 20 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 29 mentions for Veru and 9 mentions for Arrowhead Pharmaceuticals. Veru's average media sentiment score of 0.18 beat Arrowhead Pharmaceuticals' score of -0.68 indicating that Veru is being referred to more favorably in the media.
Summary
Veru beats Arrowhead Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Veru (NASDAQ:VERU) vs. Its Competitors
